Patents Assigned to Biopharma S.A.
-
Patent number: 11806313Abstract: Disclosed is a self-microemulsion system for loading abiraterone acetate, and a composition and an application thereof. The self-microemulsion system for loading abiraterone acetate has excellent solubility and stability for abiraterone acetate, and the composition formed by dissolving abiraterone acetate in this system can significantly reduce the effect of food on the absorption of abiraterone acetate, and reduce the differences between preprandial administration and postprandial administration, thus making it possible to take the medicament on both an empty and a full stomach and reducing the limitation for the time of taking medicament.Type: GrantFiled: December 12, 2022Date of Patent: November 7, 2023Assignee: HUNAN HUIZE BIOPHARMA S&T CO., LTD.Inventor: Mulin Yi
-
Publication number: 20230181465Abstract: Disclosed is a self-microemulsion system for loading abiraterone acetate, and a composition and an application thereof. The self-microemulsion system for loading abiraterone acetate has excellent solubility and stability for abiraterone acetate, and the composition formed by dissolving abiraterone acetate in this system can significantly reduce the effect of food on the absorption of abiraterone acetate, and reduce the differences between preprandial administration and postprandial administration, thus making it possible to take the medicament on both an empty and a full stomach and reducing the limitation for the time of taking medicament.Type: ApplicationFiled: December 12, 2022Publication date: June 15, 2023Applicant: Hunan Huize Biopharma S&T Co., LtdInventor: Mulin YI
-
Patent number: 11578368Abstract: The present invention provides a method of assessing type 2 diabetes susceptibility and/or predicting treatment responsiveness in a human subject, the method comprising determining the identity of at least one allele at each of three or more positions of single nucleotide polymorphism (SNP) selected from the group consisting of: SLC16A11-rs75493593; HNF1A-rs483353044; TCF7L2-rs7903146; CDKN2A/B-rs10811661; CDKAL1-rs7756992; SLC30A8-rs3802177; IGF2BP2-rs4402960; FTO-rs9936385; PPARG-rs1801282; HHEX/IDE-rs1111875; ADCYS-rs11717195; JAZF1-rs849135; WSF1-rs4458523; INS-IGF2-rs149483638; KCNQ1-rs2237897; and KCNJ11-rs5219, and/or an SNP in linkage disequilibrium with any one of said SNPs at r2>0.8. Also provided are a genotyping tool and a type 2 diabetes risk assessment system for use in the method of the invention.Type: GrantFiled: April 28, 2020Date of Patent: February 14, 2023Assignee: Patia Biopharma, S.A. De C.V.Inventors: Laureano Simón Buela, Mirella G. Zulueta
-
Publication number: 20210254135Abstract: The present invention provides a method for depleting host nucleic acid in a biological sample, said sample having been previously obtained from an animal host and having been subjected to treatment to lyse host cells present in the sample, and having been subjected to a treatment to deplete nucleic acid released from host cells within said sample or otherwise to render such nucleic acid unidentifiable, the method comprising: (a) depleting host mitochondria or host mitochondrial DNA (mtDNA) present in the treated sample; and (b) extracting and/or analysing remaining nucleic acid from the treated sample. Also provided is a related kit comprising reagents for performing the method. Further claimed is a method for isolating mitochondrial DNA after host cells have been lysed and host cell nucleic acids have been removed from the sample.Type: ApplicationFiled: June 20, 2019Publication date: August 19, 2021Applicants: PROGENIKA BIOPHARMA, S.A., UEA ENTERPRISES LIMITEDInventors: Lourdes Palacios, Nerea Bartolome, Antonio Martinez, Justin Joseph O'Grady, Gemma Louise Kay
-
Patent number: 11085082Abstract: Provided is a method of assessing Gestational Diabetes Mellitus (GDM) susceptibility in a female human subject, the method comprising determining the identity of at least one allele at each of at least two positions of single nucleotide polymorphism (SNP) selected from: TCF7L2—rs7903146; IGF2BP2—rs4402960; CDKN2A/B—rs10811661; SLC16A11—rs13342232; FTO—rs8050136; SLC30A8—rs13266634; CDC123/CAMK1D—rs12779790; KCNQ1—rs2237892; CUBN—rs11254363; CUBN—rs1801222; FIGN—rs2119289; FIGN—rs982393; MTHFR—rs1801131; MTHFR—rs1801133; MTR—rs1805087; and SLC19A1—rs1051266, and/or an SNP in linkage disequilibrium therewith at r2>0.8. Also provided are genotyping tools and risk assessment systems for use in the method of assessing GDM susceptibility.Type: GrantFiled: December 16, 2016Date of Patent: August 10, 2021Assignee: Patia Biopharma S.A. de C.V.Inventors: Laureano Simón Buela, Mirella G. Zulueta, Teresa Tusié
-
Patent number: 10864278Abstract: The present invention relates to conjugates, in particular antibody-drug conjugates and immunotoxins, having the formula I: A-(L-D)p??(I) or a pharmaceutically acceptable salts or solvates thereof, wherein: A is an antibody that selectively binds FAP; L is a linker; D is a drug comprising a cytolysin or a Nigrin-b A-chain; and p is 1 to 10, and to use of such conjugates in the therapeutic treatment of tumors. Methods of producing such conjugates and components for use in such methods are disclosed.Type: GrantFiled: October 16, 2018Date of Patent: December 15, 2020Assignee: Oncomatryx Biopharma, S.L.Inventors: Roland Kontermann, Klaus Pfizenmaier, Cristina Ferrer, Myriam Fabre, Laureano Simon
-
Patent number: 10851413Abstract: The present invention provides a method for genotyping alleles in at least one homologous genetic loci set, comprising: (i) providing a DNA-containing sample that includes said at least one homologous genetic loci set; (ii) performing PCR amplification of regions of said homologous genetic loci set using consensus sequence-specific primers, wherein said consensus sequence-specific primers bind to consensus sequences that are common to a plurality of genes within the genetic loci set, thereby generating a pool of amplification products; (iii) sequencing a plurality of said amplification products in order to determine the relative proportion of each nucleotide at each position in a sequencing read; (iv) performing a sequence alignment between the sequencing read results of (iii) and at least one reference sequence, which reference sequence corresponds to one of the genes in said homologous genetic loci set; and (v) performing genotype calling of the allele or alleles in said sample based on the relative proportType: GrantFiled: August 12, 2015Date of Patent: December 1, 2020Assignee: Progenika Biopharma S.A.Inventors: Jorge Ochoa, David Arteta, Mariá José Illescas, Monica Lopez, Marianne Stef, Diego Tejedor, Antonio Martìnez
-
Patent number: 10830779Abstract: A lateral flow immunoassay for the detection of anti-drug antibodies against a biological drug includes a membrane having a capture area, a sample application area, a flow path from the sample application area to the capture area, and a conjugate area located in the flow path. The conjugate area has said biological drug detectably labeled and the capture area has said biological drug immobilized thereto.Type: GrantFiled: July 27, 2015Date of Patent: November 10, 2020Assignee: PROGENIKA BIOPHARMA, S.A.Inventors: Antonio Martinez Martinez, Daniel Nagore Casas, Alberto Monasterio Asteinza, Nerea Torres Antúnez
-
Publication number: 20200283850Abstract: Provided is a method of assessing Gestational Diabetes Mellitus (GDM) susceptibility in a female human subject, the method comprising determining the identity of at least one allele at each of at least two positions of single nucleotide polymorphism (SNP) selected from: TCF7L2—rs7903146; IGF2BP2—rs4402960; CDKN2A/B—rs10811661; SLC16A11—rs13342232; FTO—rs8050136; SLC30A8—rs13266634; CDC123/CAMK1D—rs12779790; KCNQ1—rs2237892; CUBN—rs11254363; CUBN—rs1801222; FIGN—rs2119289; FIGN—rs982393; MTHFR—rs1801131; MTHFR—rs1801133; MTR—rs1805087; and SLC19A1—rs1051266, and/or an SNP in linkage disequilibrium therewith at r2>0.8. Also provided are genotyping tools and risk assessment systems for use in the method of assessing GDM susceptibility.Type: ApplicationFiled: December 16, 2016Publication date: September 10, 2020Applicant: Patia Biopharma, S.A. de C.V.Inventors: Laureano Simón Buela, Mirella G. Zulueta, Teresa Tusié
-
Patent number: 10538577Abstract: The invention is related to the production and development of a lyophilized injectable formulation of modified antibodies or their variants, highly specific neutralizers of heterologous mixtures of proteins, peptides and other organic or inorganic components have different specific activities and may include but are not limited to the venoms of venomous animals. For convenience, we refer to venoms, but all type of venoms was included of land and marine animals. It is also addressed to the production method which includes the hyperimmunization of mammals for the production of highly specific antibodies, the modification (fragmentation) and purification process, and finally the injectable formulation conferring thereon properties of high purity and high specificity.Type: GrantFiled: February 7, 2013Date of Patent: January 21, 2020Assignee: INOSAN BIOPHARMA S.A.Inventors: Juan Lopez De Silanes Perez, Jesús Raúl Soria Osorio
-
Publication number: 20190105406Abstract: The present invention relates to conjugates, in particular antibody-drug conjugates and immunotoxins, having the formula I: A-(L-D)p ??(I) or a pharmaceutically acceptable salts or solvates thereof, wherein: A is an antibody that selectively binds FAP; L is a linker; D is a drug comprising a cytolysin or a Nigrin-b A-chain; and p is 1 to 10, and to use of such conjugates in the therapeutic treatment of tumors. Methods of producing such conjugates and components for use in such methods are disclosed.Type: ApplicationFiled: October 16, 2018Publication date: April 11, 2019Applicant: Oncomatryx Biopharma, S.L.Inventors: Roland Kontermann, Klaus Pfizenmaier, Cristina Ferrer, Myriam Fabre, Laureano Simon
-
Patent number: 10253366Abstract: The present invention provides a method for detecting the presence or absence of, or for discriminating between, blood type variants, including RHD*r?s, RHD*DIIIa and RHD*DIVa-2. The method comprises amplifying by PCR a sample obtained from a human subject at intron 3 of the RHD gene locus. The invention also provides products, in particular, probes, primers and kits for use in the method of the invention.Type: GrantFiled: April 29, 2016Date of Patent: April 9, 2019Assignee: Progenika Biopharma, S.A.Inventors: Jorge Ochoa, Monica Lopez, Araitz Molano, Diego Tejedor, Antonio Martinez
-
Patent number: 10215762Abstract: The invention relates to the field of personalized therapy and, in particular, to a method for classifying a patient suffering from rheumatoid arthritis as a responder or as a non-responder patient to a treatment based on a biological drug.Type: GrantFiled: September 30, 2016Date of Patent: February 26, 2019Assignee: Progenika Biopharma, S.A.Inventors: Ainhoa Ruiz Del Agua, Antonio Martinez Martinez, Daniel Nagore Casas, Laureano Simon Buela
-
Patent number: 10137202Abstract: The present invention relates to conjugates, in particular antibody-drug conjugates and immunotoxins, having the formula I: A-(L-D)p (I) or a pharmaceutically acceptable salts or solvates thereof, wherein: A is an antibody that selectively binds FAP; L is a linker; D is a drug comprising a cytolysin or a Nigrin-b A-chain; and p is 1 to 10, and to use of such conjugates in the therapeutic treatment of tumors. Methods of producing such conjugates and components for use in such methods are disclosed.Type: GrantFiled: February 4, 2015Date of Patent: November 27, 2018Assignee: Oncomatryx Biopharma, S.L.Inventors: Roland Kontermann, Klaus Pfizenmaier, Cristina Ferrer, Myriam Fabre, Laureano Simon
-
Publication number: 20180305756Abstract: The present invention provides a method for genotyping alleles in at least one homologous genetic loci set, comprising: (i) providing a DNA-containing sample that includes said at least one homologous genetic loci set; (ii) performing PCR amplification of regions of said homologous genetic loci set using consensus sequence-specific primers, wherein said consensus sequence-specific primers bind to consensus sequences that are common to a plurality of genes within the genetic loci set, thereby generating a pool of amplification products; (iii) sequencing a plurality of said amplification products in order to determine the relative proportion of each nucleotide at each position in a sequencing read; (iv) performing a sequence alignment between the sequencing read results of (iii) and at least one reference sequence, which reference sequence corresponds to one of the genes in said homologous genetic loci set; and (v) performing genotype calling of the allele or alleles in said sample based on the relative proportType: ApplicationFiled: August 12, 2015Publication date: October 25, 2018Applicant: Progenika Biopharma S.A.Inventors: Jorge Ochoa, David Arteta, Mária José Illescas, Monica Lopez, Marianne Stef, Diego Tejedor, Antonio Martínez
-
Patent number: 10004812Abstract: The present invention relates to conjugates, in particular antibody-drug conjugates and immunotoxins, having the formula I: A-(L-D)p (I) or a pharmaceutically acceptable salts or solvates thereof, wherein: A is an antibody that selectively binds Endoglin; L is a linker; D is a drug comprising a cytolysin or a Nigrin-b A-chain; and p is 1 to 10, and to use of such conjugates in the therapeutic treatment of tumors. Methods of producing such conjugates and components for use in such methods are disclosed.Type: GrantFiled: February 4, 2015Date of Patent: June 26, 2018Assignee: Oncomatryx Biopharma, S.L.Inventors: Roland Kontermann, Klaus Pfizenmaier, Cristina Ferrer, Myriam Fabre, Laureano Simon
-
Patent number: 9896512Abstract: Described herein is novel isolated or synthetic peptides derived from a complementarity determining region hypervariable domain amino acid sequence of a humanized monoclonal antibody to NaPi2B transporter, as well as derivatives thereof, and a pharmaceutical composition and a method for inhibiting tumor growth or treating a tumor or cancer treating using the antitumor peptides and derivatives thereof.Type: GrantFiled: October 27, 2015Date of Patent: February 20, 2018Assignee: Recepta Biopharma S.A.Inventor: Luiz Rodolpho Raja Gabaglia Travassos
-
Patent number: 9708282Abstract: A compound has formula (I), where R is selected from a methyl group or an ethyl group: The compound can be hydroxy acid forms thereof, the pharmaceutically acceptable salts of the hydroxy acids and pharmaceutically acceptable prodrugs and solvates of the compounds and of the hydroxy acid forms thereof. The compounds can be used in the prevention or treatment of: neurodegenerative or neurological diseases, cognitive impairment, diseases with impaired APP metabolism, inflammation or inflammatory processes, or epilepsy, epileptic seizures and convulsions.Type: GrantFiled: June 5, 2014Date of Patent: July 18, 2017Assignee: NEURON BIOPHARMA, S.A.Inventors: Maria del Carmen Ramos Martín, Fernando Guzmán Sánchez, Soraya Santana Martínez, Saleta Sierra Ávila, Javier Santos Burgos Muñoz
-
Patent number: 9702879Abstract: The present invention relates to in vitro methods and products for detecting the presence of an invasive carcinoma in an individual, for determining and/or predicting the stage and/or invasiveness of said carcinoma in an individual, or for monitoring the effect of the therapy administered to an individual who has said carcinoma based on col11a1 gene and proCOL11A1 protein expression. The invention also relates to the search for, identification, development and evaluation of the efficacy of compounds for therapy for said carcinoma, for the purpose of developing new medicinal products. The invention also relates to agents inhibiting proCOL11A1 protein expression and/or activity, and/or the effects of this expression.Type: GrantFiled: August 8, 2012Date of Patent: July 11, 2017Assignee: Oncomatryx Biopharma, S.L.Inventors: Luis Barneo Serra, Carmen Garcia Pravia, Juan Ramon De Los Toyos Gonzalez, Marcos Garcia Ocana, Jose Fernando Vazquez Villa, Nelson Fuentes Martinez, Jokin Del Amo Iribarren, Laureano Simon Buela
-
Patent number: 9637788Abstract: The present invention provides a method for detecting the presence or absence of, or for discriminating between, blood type variants, including RHD*r?s, RHD*DIIIa, RHD*DIVa-2, RHCE*css and RHCE*ce733G. The method comprises genotyping a sample obtained from a human subject at one or more positions in intron 7 of the RHD gene and/or in intron 7 of the RHCE gene. The invention also provides products, in particular, probes, primers and kits for use in the method of the invention.Type: GrantFiled: June 14, 2012Date of Patent: May 2, 2017Assignee: Progenika Biopharma, S.A.Inventors: Jorge Ochoa, Monica Lopez, Sergio Escorza, Diego Tejedor, Antonio Martinez, Laureano Simon